468 related articles for article (PubMed ID: 31838011)
1. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
[TBL] [Abstract][Full Text] [Related]
2. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
4. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.
Bajpai J; Kapu V; Rath S; Kumar S; Sekar A; Patil P; Siddiqui A; Anne S; Pawar A; Srinivas S; Bhargava P; Gulia S; Noronha V; Joshi A; Prabhash K; Banavali S; Sarin R; Badwe R; Gupta S
Lancet Oncol; 2024 Feb; 25(2):246-254. PubMed ID: 38224701
[TBL] [Abstract][Full Text] [Related]
5. Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.
Hashimoto H; Abe M; Yanai T; Yamaguchi T; Zenda S; Uchitomi Y; Fukuda H; Mori M; Iwasa S; Yamamoto N; Ohe Y
Jpn J Clin Oncol; 2018 Oct; 48(10):950-952. PubMed ID: 30124989
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.
Abe M; Yamaguchi T; Fujita Y; Nishimura T; Kitagawa K; Inui N; Hirano K; Sakata Y; Iihara H; Shibuya Y; Suzuki K; Shibata K; Hori K; Daga H; Nakayama T; Sakata Y; Takahashi TY; Zenda S; Hashimoto H
JAMA Netw Open; 2023 May; 6(5):e2310894. PubMed ID: 37129897
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study).
Zhao Y; Yang Y; Gao F; Hu C; Zhong D; Lu M; Yuan Z; Zhao J; Miao J; Li Y; Zhu J; Wang C; Han J; Zhao Y; Huang Y; Zhang L
EClinicalMedicine; 2023 Jan; 55():101771. PubMed ID: 36712888
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
[TBL] [Abstract][Full Text] [Related]
11. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
14. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.
Wang DS; Hu MT; Wang ZQ; Ren C; Qiu MZ; Luo HY; Jin Y; Fong WP; Wang SB; Peng JW; Zou QF; Tan Q; Wang FH; Li YH
JAMA Netw Open; 2021 Apr; 4(4):e215250. PubMed ID: 33835174
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Roila F; Ruggeri B; Ballatori E; Fatigoni S; Caserta C; Licitra L; Mirabile A; Ionta MT; Massidda B; Cavanna L; Palladino MA; Tocci A; Fava S; Colantonio I; Angelelli L; Ciuffreda L; Fasola G; Zerilli F
Ann Oncol; 2015 Jun; 26(6):1248-1253. PubMed ID: 25743855
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
18. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Yanai T; Iwasa S; Hashimoto H; Ohyanagi F; Takiguchi T; Takeda K; Nakao M; Sakai H; Nakayama T; Minato K; Arai T; Suzuki K; Shimada Y; Nagashima K; Terakado H; Yamamoto N
Int J Clin Oncol; 2018 Apr; 23(2):382-388. PubMed ID: 29039073
[TBL] [Abstract][Full Text] [Related]
19. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
[TBL] [Abstract][Full Text] [Related]
20. Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
Minatogawa H; Izawa N; Kawaguchi T; Miyaji T; Shimomura K; Kazunori H; Iihara H; Ohno Y; Inada Y; Arioka H; Morita H; Hida N; Sugawara M; Katada C; Nawata S; Ishida H; Tsuboya A; Tsuda T; Yamaguchi T; Nakajima TE
BMJ Open; 2020 Dec; 10(12):e041737. PubMed ID: 33334838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
